NASDAQ:KA Kineta (KA) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free KA Stock Alerts $0.53 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.41▼$0.5750-Day Range$0.52▼$2.8352-Week Range$0.41▼$5.39Volume139,453 shsAverage Volume104,258 shsMarket Capitalization$5.76 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Kineta alerts: Email Address Kineta MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,422.9% Upside$8.00 Price TargetShort InterestHealthy1.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.15) to ($1.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 stars 3.5 Analyst's Opinion Consensus RatingKineta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Kineta has a forecasted upside of 1,422.9% from its current price of $0.53.Amount of Analyst CoverageKineta has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.00% of the float of Kineta has been sold short.Short Interest Ratio / Days to CoverKineta has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kineta has recently increased by 276.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKineta does not currently pay a dividend.Dividend GrowthKineta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KA. Previous Next 3.9 News and Social Media Coverage News SentimentKineta has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kineta this week, compared to 1 article on an average week.Search Interest2 people have searched for KA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Kineta to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kineta insiders have not sold or bought any company stock.Percentage Held by Insiders29.80% of the stock of Kineta is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.32% of the stock of Kineta is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kineta are expected to decrease in the coming year, from ($1.15) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kineta is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kineta is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKineta has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Kineta Stock (NASDAQ:KA)Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.Read More KA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KA Stock News HeadlinesMarch 22, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 21, 2024 | globenewswire.comKineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 12, 2024 | globenewswire.comKVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data ReportedMarch 1, 2024 | bizjournals.comKineta CEO laid off as cutbacks leave biotech with 4 employeesFebruary 29, 2024 | msn.comKineta stock falls ~25.7% after co cuts workforce by 64%, including CEOFebruary 29, 2024 | globenewswire.comKineta Announces Restructuring and Exploration of Strategic AlternativesFebruary 22, 2024 | finance.yahoo.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumMarch 29, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 22, 2024 | globenewswire.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 14, 2024 | finance.yahoo.comKineta to Present at Upcoming Investor ConferencesFebruary 14, 2024 | globenewswire.comKineta to Present at Upcoming Investor ConferencesFebruary 7, 2024 | stockhouse.comKineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat SeriesJanuary 29, 2024 | finance.yahoo.comKA: Phase I/II UpdateJanuary 17, 2024 | finanznachrichten.deKineta, Inc.: Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid TumorsDecember 13, 2023 | finance.yahoo.comKineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for CancerDecember 12, 2023 | finance.yahoo.comKineta to Present at the Life Sciences Investor Forum December 14thNovember 28, 2023 | finance.yahoo.comKineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023November 9, 2023 | finance.yahoo.comKineta to Present at the 5th Annual Macrophage-Directed Therapies SummitNovember 8, 2023 | markets.businessinsider.comBuy Rating for Kineta Backed by Promising Drug Trials and Solid Financial PerformanceNovember 7, 2023 | msn.comKA: Third Quarter Results - MSNNovember 7, 2023 | finance.yahoo.comKA: Third Quarter ResultsNovember 6, 2023 | benzinga.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 6, 2023 | finance.yahoo.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNovember 4, 2023 | finance.yahoo.comKineta Insider Purchases Yet To Pay Off Regardless Of Recent StrengthNovember 4, 2023 | finanznachrichten.deKineta, Inc.: Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 3, 2023 | benzinga.comKineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingSee More Headlines Receive KA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kineta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KA CUSIPN/A CIK1445283 Webwww.kinetabio.com Phone(206) 378-0400FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,422.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,100,000.00 Net Margins-769.29% Pretax Margin-258.65% Return on Equity-453.89% Return on Assets-118.90% Debt Debt-to-Equity Ratio0.05 Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$5.44 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book1.81Miscellaneous Outstanding Shares10,960,000Free Float7,695,000Market Cap$5.76 million OptionableNot Optionable Beta0.53 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Craig W. Philips (Age 63)President Comp: $485.79kMs. Pauline Kenny Esq. (Age 50)J.D., Advisor Comp: $349.72kMr. Keith A. Baker (Age 57)Chief Financial Officer Dr. Thierry Guillaudeux Ph.D. (Age 57)Chief Scientific Officer Gary GentgesExecutive Vice President of Corporate DevelopmentKey CompetitorsYumanity TherapeuticsNASDAQ:YMTXNexImmuneNASDAQ:NEXIEnsysce BiosciencesNASDAQ:ENSCXenetic BiosciencesNASDAQ:XBIOPulmatrixNASDAQ:PULMView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 76,822 shares on 3/11/2024Ownership: 1.457%Vanguard Group Inc.Bought 76,822 shares on 2/15/2024Ownership: 1.456%Citadel Advisors LLCBought 10,015 shares on 2/15/2024Ownership: 0.096%Armistice Capital LLCSold 104,208 shares on 2/13/2024Ownership: 7.948%Northern Trust CorpBought 36,880 shares on 2/13/2024Ownership: 0.355%View All Insider TransactionsView All Institutional Transactions KA Stock Analysis - Frequently Asked Questions Should I buy or sell Kineta stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kineta in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KA shares. View KA analyst ratings or view top-rated stocks. What is Kineta's stock price target for 2024? 1 brokerages have issued 12 month price targets for Kineta's shares. Their KA share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 1,422.9% from the stock's current price. View analysts price targets for KA or view top-rated stocks among Wall Street analysts. How have KA shares performed in 2024? Kineta's stock was trading at $3.63 at the beginning of the year. Since then, KA stock has decreased by 85.5% and is now trading at $0.5253. View the best growth stocks for 2024 here. Are investors shorting Kineta? Kineta saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 75,300 shares, an increase of 276.5% from the February 29th total of 20,000 shares. Based on an average daily trading volume, of 96,900 shares, the short-interest ratio is presently 0.8 days. Approximately 1.0% of the shares of the stock are short sold. View Kineta's Short Interest. When is Kineta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KA earnings forecast. Who are Kineta's major shareholders? Kineta's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (7.95%), Vanguard Group Inc. (1.46%), Vanguard Group Inc. (1.46%), Northern Trust Corp (0.35%), Stifel Financial Corp (0.21%) and Citadel Advisors LLC (0.10%). Insiders that own company stock include Craig W Philips, Keith Baker, Pauline Kenny, Raymond J Bartoszek, Shawn Iadonato and Thierry Guillaudeux. View institutional ownership trends. How do I buy shares of Kineta? Shares of KA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsOnly a fool would buy Nvidia today… Porter & CompanyBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kineta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.